Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 245 First Street CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://akebia.com |
IR: | See website |
Key People | ||
John P. Butler President, Chief Executive Officer, Interim Principal Financial Officer, Director | Michel Dahan Chief Operating Officer, Senior Vice President | Nicole R. Hadas Senior Vice President, Chief Legal Officer, Corporate Secretary |
Steven K. Burke Senior Vice President - Research and Development, Chief Medical Officer | Richard C. Malabre Chief Accounting Officer | Nicholas Grund Chief Commercial Officer |
Business Overview |
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company's portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Akebia Therapeutics Inc revenues decreased 33% to $194.6M. Net loss decreased 45% to $51.9M. Revenues reflect License, collaboration and other revenue decrease of 79% to $24.3M, Product revenue, net decrease of 4% to $170.3M. Lower net loss reflects Research and development - Balancing val decrease of 52% to $61.1M (expense), Valuation of Inventory - Gain/Loss decrease of 95% to $1.6M (expense). |
Employees: | 167 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $282.79M as of Dec 31, 2023 |
Annual revenue (TTM): | $194.62M as of Dec 31, 2023 |
EBITDA (TTM): | -$8.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$51.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$23.38M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 209,372,275 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |